1
|
Yu YM, Li XJ, Bu FZ, Zhao ZL, Wu ZY, Li YT. Drug-Drug Cocrystal Alloy and Nanoformulation of Cytarabine: Optimized Biopharmaceutical Property and Synergistic Antitumor Efficacy. Mol Pharm 2024. [PMID: 39392428 DOI: 10.1021/acs.molpharmaceut.4c00733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/12/2024]
Abstract
An integrated strategy by combining cocrystallization with nanotechnology is developed to optimize in vitro/vivo performances of marine antitumor drug cytarabine (ARA) and further obtain innovative insights into the exploitation of cocrystal alloy nanoformulation. Therein, the optimization of properties and synergistic effects of ARA mainly depends on assembling with uracil (U) and antitumor drug 5-fluorouracil (FU) into the same crystal by cocrystallization technology, while the long-term efficacy is primarily maintained by playing the superiority of nanotechnology. Along this line, the first cocrystal alloy of ARA, viz., ARA-FU-U (0.6:0.4), is successfully obtained and then transformed into a nanocrystal. Single-crystal X-ray diffraction analysis demonstrates that this cocrystal alloy consists of two isomorphic cocrystals of ARA, namely, ARA-FU and ARA-U, in 0.6:0.4 ratio. An R22(8) hydrogen-bonding cyclic system formed by a cytosine fragment of ARA with U or FU can protect and stabilize the amine group on ARA, laying the foundation for regulating its properties. The in vitro/in vivo properties of the cocrystal alloy and its nanocrystals are investigated by theoretical and experimental means. It reveals that both the alloy and nanocrystal can improve physicochemical properties and promote drug absorption, thus bringing to optimized pharmacokinetic behaviors. The nanocrystal produces superior effects than the alloy that helps to extend therapeutic time and action. Particularly, relative to the corresponding binary cocrystal, the synergistic antitumor activity of ARA and FU in the cocrystal alloy is heightened obviously. It may be that U contributes to reducing the degradation of FU, specifically increasing its concentration in tumors to enhance the synergistic effects of FU and ARA. These findings provide new thoughts for the application of cocrystal alloys in the marine drug field and break fresh ground for cocrystal alloy formulations to optimize drug properties.
Collapse
Affiliation(s)
- Yue-Ming Yu
- Laboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science, Qingdao, Shandong 266234, PR China
- School of Medicine, Linyi University, Linyi, Shandong 276000, PR China
| | - Xue-Jie Li
- Qingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong 266071, PR China
| | - Fan-Zhi Bu
- Laboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science, Qingdao, Shandong 266234, PR China
- School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, PR China
| | - Zhi-Long Zhao
- School of Medicine, Linyi University, Linyi, Shandong 276000, PR China
| | - Zhi-Yong Wu
- Laboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science, Qingdao, Shandong 266234, PR China
- School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, PR China
| | - Yan-Tuan Li
- Laboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science, Qingdao, Shandong 266234, PR China
- School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, PR China
| |
Collapse
|
2
|
Jin SE, Seo CS, Jeon WY, Oh YJ, Shin HK, Jeong HG, Ha H. Evodiae Fructus extract suppresses inflammatory response in HaCaT cells and improves house dust mite-induced atopic dermatitis in NC/Nga mice. Sci Rep 2024; 14:472. [PMID: 38172219 PMCID: PMC10764943 DOI: 10.1038/s41598-023-50257-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Accepted: 12/18/2023] [Indexed: 01/05/2024] Open
Abstract
This study was conducted to assess the effect of Evodiae Fructus 70% ethanol extract (EFE) on the pathology of atopic dermatitis using in vitro and in vivo models. The major compounds in EFE were identified by ultra-performance liquid chromatography with tandem mass spectrometry as rutaecarpine, evodiamine, evodol, dehydroevodiamine, limonin, synephrine, evocarpine, dihydroevocarpine, and hydroxyevodiamine. EFE significantly decreased chemokine levels in tumor necrosis factor-α/interferon-γ-stimulated HaCaT cells. In house dust mite-treated NC/Nga mice, topical application of EFE significantly decreased the dermatitis score, epidermal hyperplasia and thickening, mast cell infiltration, and plasma levels of histamine and corticosterone. Thymic stromal lymphopoietin, CD4+ T cells, interleukin-4, and intercellular adhesion molecule-1 expression in the lesioned skin was reduced in the treated mice. The mechanism of EFE was elucidated using transcriptome analysis, followed by experimental validation using Western blotting in HaCaT cells. EFE down-regulated the activation of Janus kinase (JAK)-signal transducers and activators of transcription (STAT) and mitogen-activated protein kinases (MAPK) signaling pathways in HaCaT cells. EFE improves atopic dermatitis-like symptoms by suppressing inflammatory mediators, cytokines, and chemokines by regulating the JAK-STAT and MAPK signaling pathways, suggesting its use as a potential agent for the treatment of atopic dermatitis.
Collapse
Affiliation(s)
- Seong Eun Jin
- KM Science Research Division, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea
- College of Pharmacy, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon, 34134, Republic of Korea
| | - Chang-Seob Seo
- KM Science Research Division, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea
| | - Woo-Young Jeon
- KM Convergence Research Division, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea
| | - Yong Jin Oh
- KM Science Research Division, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea
| | - Hyeun-Kyoo Shin
- KM Science Research Division, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea
| | - Hye Gwang Jeong
- College of Pharmacy, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon, 34134, Republic of Korea.
| | - Hyekyung Ha
- KM Science Research Division, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea.
| |
Collapse
|
3
|
Yu YM, Bu FZ, Meng SS, Yan CW, Wu ZY, Li YT. The first marine dual-drug cocrystal of cytarabine with 5-fluorouracil having synergistic antitumor effects shows superior biopharmaceutical peculiarities by oral administration. Int J Pharm 2022; 629:122386. [DOI: 10.1016/j.ijpharm.2022.122386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2022] [Revised: 10/20/2022] [Accepted: 11/06/2022] [Indexed: 11/13/2022]
|
4
|
Zhou X, Münch G, Wohlmuth H, Afzal S, Kao MH(T, Al-Khazaleh A, Low M, Leach D, Li CG. Synergistic Inhibition of Pro-Inflammatory Pathways by Ginger and Turmeric Extracts in RAW 264.7 Cells. Front Pharmacol 2022; 13:818166. [PMID: 35662723 PMCID: PMC9160922 DOI: 10.3389/fphar.2022.818166] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Accepted: 04/13/2022] [Indexed: 12/27/2022] Open
Abstract
Synergy plays a prominent role in herbal medicines to increase potency and widen the therapeutic windows. The mechanism of synergy in herbal medicines is often associated with multi-targeted behavior and complex signaling pathways which are challenging to elucidate. This study aims to investigate the synergistic mechanism of a combination (GT) of ginger (G) and turmeric (T) extracts by exploring the modulatory activity in lipopolysaccharides (LPS)-induced inflammatory pathways and key molecular targets. A Bioplex ProTM mouse cytokine 23-plex assay was utilized to assess the broad anti-cytokine activity of GT in LPS and interferon (IFN)-ɣ (both at 50 ng/mL)-activated RAW 264.7 cells. The inhibitory effects of individual and combined G and T on major proinflammatory mediators including nitric oxide (NO), tumor necrosis factor (TNF) and interleukin (IL)-6 were tested using Griess reagents and ELISA assays, respectively. Immunofluorescent staining and Western blot were used to investigate the modulatory effect of GT on key proteins in the LPS/TLR4 signaling transduction. The regulation of murine microRNA miR-155-5p was tested using real-time PCR. The IC50 value and combination index (CI) values were used to demonstrate potency and synergistic interaction, respectively. GT synergistically attenuated a range of pro-inflammatory mediators including inducible NO, major cytokines (TNF and IL-6) and secondary inflammatory cytokines (GM-CSF and MCP-1). GT significantly inhibited LPS-induced NF-kB p65 translocation, the activation of TLR4, TRAF6, and phosphorylation of JNK and c-JUN. Moreover, the suppressive effect of GT on each of the protein targets in this axis was stronger than that of the individual components. Real-time PCR analysis showed that GT suppressed miR-155-5p to a greater extent than G or T alone in LPS-stimulated cells. Our study demonstrates the synergistic mechanism of GT in downregulating LPS-induced proinflammatory pathways at the miRNA and protein levels. Our results establish a scientific basis for the combined application of G and T as an advanced therapeutic candidate in inflammatory diseases with broad and synergistic anti-inflammatory activity and multi-targeted mechanisms.
Collapse
Affiliation(s)
- Xian Zhou
- NICM Health Research Institute, Western Sydney University, Westmead, NSW, Australia
| | - Gerald Münch
- School of Medicine, Western Sydney University, Campbelltown, NSW, Australia
| | - Hans Wohlmuth
- NICM Health Research Institute, Western Sydney University, Westmead, NSW, Australia
- Integria Healthcare, Eight Mile Plains, QLD, Australia
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia
| | - Sualiha Afzal
- School of Medicine, Western Sydney University, Campbelltown, NSW, Australia
| | - Ming-Hui (Tim) Kao
- School of Medicine, Western Sydney University, Campbelltown, NSW, Australia
| | - Ahmad Al-Khazaleh
- NICM Health Research Institute, Western Sydney University, Westmead, NSW, Australia
| | - Mitchell Low
- NICM Health Research Institute, Western Sydney University, Westmead, NSW, Australia
| | - David Leach
- Integria Healthcare, Eight Mile Plains, QLD, Australia
| | - Chun Guang Li
- NICM Health Research Institute, Western Sydney University, Westmead, NSW, Australia
| |
Collapse
|
5
|
Suksaeree J, Wunnakup T, Monton C. Synergistic antioxidant activity of plant compositions contained in Chatuphalathika herbal recipe: Terminalia chebula Retz. var. chebula, Terminalia arjuna Wight and Arn., Terminalia bellirica (Gaertn.) Roxb., and Phyllanthus emblica L. ADVANCES IN TRADITIONAL MEDICINE 2021. [DOI: 10.1007/s13596-021-00585-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
6
|
Lee J, Choi HS, Lee J, Park J, Kim SB, Shin MS, Lee S, Hwang GS, Koo BA, Kang KS. Preparation of Herbal Formulation for Inflammatory Bowel Disease Based on In Vitro Screening and In Vivo Evaluation in a Mouse Model of Experimental Colitis. Molecules 2019; 24:molecules24030464. [PMID: 30696085 PMCID: PMC6384830 DOI: 10.3390/molecules24030464] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2018] [Revised: 01/19/2019] [Accepted: 01/25/2019] [Indexed: 01/08/2023] Open
Abstract
Many medicinal plants have been used traditionally in East Asia for the treatment of gastrointestinal disease and inflammation. The aim of this study was to evaluate the anti-inflammatory activity of 350 extracts (175 water extracts and 175 ethanol extracts) from 71 single plants, 97 mixtures of two plants, and seven formulations based on traditional medicine, to find herbal formulations to treat inflammatory bowel disease (IBD). In the in vitro screening, nitric oxide (NO), tumor necrosis factor (TNF)-α, and interleukin (IL)-6 levels were determined in LPS-treated RAW264.7 cells and the TNF-α induced monocyte-epithelial cell adhesion assay was used for the evaluation of the anti-inflammatory activity of the compounds. Dextran sulfate sodium (DSS)-induced colitis model and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis model were used to evaluate the therapeutic effect against IBD of the samples selected from the in vitro screening. KM1608, composed of Zingiber officinale, Terminalia chebula and Aucklandia lappa, was prepared based on the screening experiments. The oral administration of KM1608 significantly attenuated the severity of colitis symptoms, such as weight loss, diarrhea, and rectal bleeding, in TNBS-induced colitis. In addition, inflammatory mediators, such as myeloperoxidase, TNF-α, and IL-6 levels decreased in the lysate of colon tissues treated with KM1608. Collectively, KM1608 ameliorated colitis through the regulation of inflammatory responses within the colon, which indicated that KM1608 had potential for the treatment of IBD.
Collapse
Affiliation(s)
- Jaemin Lee
- College of Korean Medicine, Gachon University, Seongnam-si, Gyeonggi-do 13120, Korea.
| | - Han-Seok Choi
- New Drug Research Team, Kolmar, Korea Co. Ltd., Sandan-gil, Jeonui-myeon, Sejong-si 30003, Korea.
| | - Jinkyung Lee
- College of Korean Medicine, Gachon University, Seongnam-si, Gyeonggi-do 13120, Korea.
| | - Jimin Park
- New Drug Research Team, Kolmar, Korea Co. Ltd., Sandan-gil, Jeonui-myeon, Sejong-si 30003, Korea.
| | - Sang-Back Kim
- New Drug Research Team, Kolmar, Korea Co. Ltd., Sandan-gil, Jeonui-myeon, Sejong-si 30003, Korea.
| | - Myoung-Sook Shin
- College of Korean Medicine, Gachon University, Seongnam-si, Gyeonggi-do 13120, Korea.
| | - Sullim Lee
- College of Bio-Nanotechnology, Gachon University, Seongnam-si, Gyeonggi-do 13120, Korea.
| | - Gwi Seo Hwang
- College of Korean Medicine, Gachon University, Seongnam-si, Gyeonggi-do 13120, Korea.
| | - Bon Am Koo
- New Drug Research Team, Kolmar, Korea Co. Ltd., Sandan-gil, Jeonui-myeon, Sejong-si 30003, Korea.
| | - Ki Sung Kang
- College of Korean Medicine, Gachon University, Seongnam-si, Gyeonggi-do 13120, Korea.
| |
Collapse
|